Cargando…

M172. POLYGENIC RISK SCORES ANALYSES IN ANTIPSYCHOTIC-INDUCED WEIGHT GAIN

BACKGROUND: Antipsychotic-induced weight gain (AIWG) is a common and serious side effect with antipsychotic medications, which frequently leads to obesity and metabolic disorders. Previous single-gene analyses have shown an overlap between AIWG and genes associated with obesity and energy homeostasi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Kazunari, Maciukiewicz, Malgorzata, Marshe, Victoria, Tiwari, Arun, Brandl, Eva, Lieberman, Jeffrey, Meltzer, Herbert, Kennedy, James, Mueller, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session II
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234358/ http://dx.doi.org/10.1093/schbul/sbaa030.484

Ejemplares similares

F1. GENOME-WIDE ASSOCIATION STUDIES SUGGESTED ASSOCIATION BETWEEN DGKB AND ANTIPSYCHOTIC INDUCED WEIGHT GAIN IN EUROPEANS AND AFRICAN AMERICANS
por: Maciukiewicz, Malgorzata, et al.
Publicado: (2018)

172. Sleep Quality in Overweight Adolescents during COVID-19 Lockdown
por: Moeda, Sofia, et al.
Publicado: (2023)

M47. AKATHISIA AND ATYPICAL ANTIPSYCHOTICS: EXPLORING ASSOCIATIONS TO SUICIDALITY AND AGITATION
por: Bjarke, Jill, et al.
Publicado: (2020)

M203. ANTIPSYCHOTIC-LIKE EFFECT OF DOXYCYCLINE IN PSYCHOTOMIMETICS SYMPTOMS INDUCED BY AMPHETAMINE
Publicado: (2020)

M109. WEIGHT GAIN AND THE PATHOPHYSIOLOGY OF SCHIZOPHRENIA
Publicado: (2020)

M213. COMPARISON OF LONG-TERM ANTIPSYCHOTIC USE DATA FROM MEDICAL RECORDS AND NATIONAL PRESCRIPTION REGISTER
Publicado: (2020)

M199. COPY NUMBER VARIANCE (CNV) ANALYSIS TO DETERMINE OPTIMAL ANTIPSYCHOTIC DOSAGE IN SCHIZOPHRENIA: A PILOT STUDY
por: Adanty, Christopher, et al.
Publicado: (2020)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

M169. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPUS SUBFIELD VOLUMES IN ANTIPSYCHOTIC-NAIVE FIRST EPISODE PSYCHOSIS SUBJECTS AND RELATIONSHIPS TO DURATION OF UNTREATED PSYCHOSIS
Publicado: (2020)

M159. PSYCHOTIC-LIKE EXPERIENCES, POLYGENIC RISK SCORES FOR SCHIZOPHRENIA AND STRUCTURAL PROPERTIES OF THE SALIENCE, DEFAULT MODE AND CENTRAL-EXECUTIVE NETWORKS IN HEALTHY PARTICIPANTS FROM UK BIOBANK
Publicado: (2020)

M157. A MULTICENTRE STUDY OF 1H-MRS BRAIN GLUTAMATE LEVELS IN SCHIZOPHRENIA; INVESTIGATING THE EFFECT OF ANTIPSYCHOTIC MEDICATION, SYMPTOM SEVERITY AND AGE
por: Merritt, Kate, et al.
Publicado: (2020)

M148. NORMALIZATION IN REWARD PROCESSING DURING INITIAL TREATMENT MAY PREDICT LONG-TERM CLINICAL OUTCOME IN ANTIPSYCHOTIC NAïVE SCHIZOPHRENIA PATIENTS
por: Nielsen, Mette, et al.
Publicado: (2020)

M201. MODERATORS OF WEIGHT GAIN IN RANDOMIZED CONTROLLED TRIALS OF SCHIZOPHRENIA – A META-REGRESSION ANALYSIS
por: Schneider-Thoma, Johannes, et al.
Publicado: (2020)

T192. THE GUT MICROBIOME IN SCHIZOPHRENIA AND ANTIPSYCHOTIC INDUCED METABOLIC DYSFUNCTION
por: Kanji, Sarah, et al.
Publicado: (2018)

M105. ACTIGRAPHIC MONITORING OF SLEEP-WAKE CYCLE IN SCHIZOPHRENIA OUTPATIENTS RECEIVING A LONG-ACTING INJECTABLE ANTIPSYCHOTIC: FEASIBILITY AND INITIAL RESULTS FROM A PROSPECTIVE RCT
por: Yagoda, Sergey, et al.
Publicado: (2020)

M143. REGIONAL CEREBRAL BLOOD FLOW IN INITIALLY ANTIPSYCHOTIC-NAïVE PATIENTS WITH SCHIZOPHRENIA OR PSYCHOSIS: EFFECTS OF PARTIAL D2 RECEPTOR AGONISM AND ASSOCIATION WITH SYMPTOM IMPROVEMENT
por: Bojesen, Kirsten, et al.
Publicado: (2020)

M86. CAN WEIGHT GAIN CAUSE METABOLIC SYNDROME A DECADE LATER IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDER?
por: Hawar, Moradi, et al.
Publicado: (2020)

M197. SEASONAL ANTIPSYCHOTICS IN SCHIZOPHRENIA: OUTCOMES IN NATURALISTIC SETTINGS (SEASONS STUDY) OBSERVATIONAL RETROSPECTIVE MULTICENTRE CANADIAN STUDY ON 3MONTH-FORMULATION OF LONG-ACTING INJECTABLE PALIPERIDONE PALMITATE
por: Corbeil, Olivier, et al.
Publicado: (2020)

M63. TRANSDIAGNOSTIC NEUROCOGNITIVE DEFICITS IN PSYCHIATRY: A REVIEW OF META-ANALYSES
por: East-Richard, Caroline, et al.
Publicado: (2020)

M173. RISK OF SCHIZOPHRENIA AMONG INDIVIDUALS OF AFRICAN AND LATINO ANCESTRY: THE GENOMIC PSYCHIATRY COHORT (GPC) ANALYSES
Publicado: (2020)

The Complex Relationship between Antipsychotic-Induced Weight Gain and Therapeutic Benefits: A Systematic Review and Implications for Treatment
por: Raben, Alex T., et al.
Publicado: (2018)

Catechol-O-Methyltransferase Val158Met Polymorphism and Clinical Response to Antipsychotic Treatment in Schizophrenia and Schizo-Affective Disorder Patients: a Meta-Analysis
por: Huang, Eric, et al.
Publicado: (2016)

M67. UNDERSTANDING SOCIAL COGNITION IN SCHIZOPHRENIA THROUGH THE LENS OF SCHIZOTYPY
por: Lee, Sara-Ann, et al.
Publicado: (2020)

M38. PATIENT-PERSPECTIVE: NEED FOR CARE AFTER A FIRST PSYCHOSIS
por: Heijden-Hobus, Inge, et al.
Publicado: (2020)

M73. DRIVING ABILITIES IN PATIENTS WITH SCHIZOPHRENIA
por: Pardeller, Silvia, et al.
Publicado: (2020)

M31. THE ASSOCIATION BETWEEN BULLYING VICTIMIZATION AND PSYCHOSIS AND THE MEDIATING ROLE OF PEER AND FAMILY SOCIAL SUPPORT
por: Shannon, Ciaran, et al.
Publicado: (2020)

M246. DIGITAL SELF-MONITORING AND EMBODIMENT IN FIRST EPISODE PSYCHOSIS: ETHICAL CONSIDERATIONS
por: Berkhout, Susan, et al.
Publicado: (2020)

M49. BEHAVIOURAL SOCIAL COGNITION IN SCHIZOPHRENIA SPECTRUM DISORDERS IN COMPARISON TO AUTISM SPECTRUM DISORDER: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Oliver, Lindsay, et al.
Publicado: (2020)

M1. INVESTIGATING THE RELATIONSHIP BETWEEN CHILDHOOD TRAUMA AND PSYCHIATRIC DISEASE USING MACHINE LEARNING TECHNIQUES
por: Haidl, Theresa, et al.
Publicado: (2020)

M12. INCREASED SAFETY BEHAVIOR IN SUBJECTS WITH CHILDHOOD TRAUMA AND DELUSIONS
por: Conring, Frauke, et al.
Publicado: (2020)

M46. THE STUDY OF HEART RATE VARIABILITY AND EMOTIONAL RESPONSE TO POSITIVE AND NEGATIVE AUDIOVISUAL STIMULATION IN PATIENTS WITH SCHIZOPHRENIA
por: Jang, Seung-Ho, et al.
Publicado: (2020)

M18. REDUCED CORTICAL CEREBRAL BLOOD FLOW IN FIRST EPISODE PSYCHOSIS PATIENTS
por: Selvaggi, Pierluigi, et al.
Publicado: (2020)

M82. GROWING BURDEN OF DISEASE: THE PREVALENCE OF CHRONIC HEALTH CONDITIONS AFTER A FIRST EPISODE OF PSYCHOSIS
por: Rodrigues, Myanca, et al.
Publicado: (2020)

M226. ECOLOGICAL MOMENTARY ASSESSMENT OF REAL-WORLD FUNCTIONING IN SCHIZOPHRENIA: MODERATING EFFECTS OF COGNITIVE AND FUNCTIONAL ABILITY STATUS
por: Mahmood, Zanjbeel, et al.
Publicado: (2020)

M41. TRAJECTORIES AND PREDICTORS OF OUTCOME IN SCHIZOPHRENIA: THE BENEFICIAL ROLE OF AMISULPRIDE
por: Drosos, Petros, et al.
Publicado: (2020)

M24. NETWORK STRUCTURE OF PSYCHOPATHOLOGY SYMPTOMS IN A COMMUNITY SAMPLE OF YOUTH
por: Wang, Emily, et al.
Publicado: (2020)

M30. THE ASSOCIATION OF PEER-REPORTED BULLYING AND SOCIAL NETWORK CHARACTERISTICS WITH PSYCHOTIC EXPERIENCES IN CHILDHOOD
por: Steenkamp, Lisa, et al.
Publicado: (2020)

M9. RATS REARED IN SOCIAL ISOLATION INDUCES EPIGENETIC MODIFICATIONS IN THE NMDA RECEPTOR SUBUNITS
por: Loureiro, Camila, et al.
Publicado: (2020)

M231. INTERNALIZED STIGMA AS A PREDICTOR OF EMPLOYMENT STATUS IN PATIENTS WITH SCHIZOPHRENIA
por: Yi Sum, Min, et al.
Publicado: (2020)

M240. THE RELATIONSHIP OF TREATMENT DELAY WITH PERSONALITY TRAIT AND FAMILY COHESION IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA SPECTRUM DISORDER
por: Jo, Anna, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h98033s8o61oblpgj2o7of33q1